Syringe adapter and guide for filling an on-body injector

ABSTRACT

A system and a method for filling an on-body injector includes a needle of the prefilled syringe being aligned with a fill port of the on-body injector. The needle may then be inserted into a guide of a needle cover attached to the on-body injector. An adapter attached to the syringe barrel may guide the needle into a center of the bore of the guide and into the fill port of the on-body injector. The needle may be inserted into the fill port and the adapter may be mechanically coupling to the guide. After the adapter is mechanically coupled to the guide, a volume of the drug of the prefilled syringe may be dispensed into a reservoir of the on-body injector. Once the reservoir is filled to a desired amount, the needle may be removed from the fill port by decoupling the adapter from the guide.

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a continuation of U.S. patent application Ser. No. 16/095,018,filed Oct. 19, 2018, which is the United States national phase of andclaims priority to International Patent Application No. PCT/US17/29109,filed Apr. 24, 2017, which claims priority to U.S. Provisional PatentApplication No. 62/330,354, filed May 2, 2016, the entire contents ofeach of which are hereby expressly incorporated by reference herein.

FIELD OF THE DISCLOSURE

The present disclosure is directed to filling a drug delivery deviceand, in particular, to a method and system for filling an on-bodyinjector using a syringe adapter and guide.

BACKGROUND

An on-body injector is a disposable drug delivery device and offers aconvenient method for self-administering a drug. An on-body injector mayadhere to a patient's skin and may be programmed to inject an insertionneedle into the patient's skin to deliver a drug when the device isactivated. After drug delivery is complete, the needle can retract backinto the device housing and the patient may remove and dispose of thedevice.

FIGS. 1 and 2 illustrate a known system and method for filling anon-body injector 10 with a drug using a prefilled syringe 12. Typically,a healthcare provider may fill an empty device 10 with a protectiveneedle cover 14 attached to an underside surface of the device 10. Theneedle cover 14 seals the device to keep a fill port 16 and a drugdelivery opening 15 sterile while also providing a syringe guide 20 forfilling the device 10. The healthcare provider may align a needle 22 ofthe syringe 12 with the fill port 16 and then insert the needle 22through a bore 24 of the guide 20 and into the fill port 16 of thedevice.

FIG. 2 illustrates a cross-sectional view of the guide 20, illustratingthe syringe 12 in position for filling a reservoir 18 of the on-bodyinjector 10. A top surface 28 of the guide 20 meets a lower surface 36of a distal end 30 of the syringe 12 when the syringe 12 is insertedinto the bore 24 of the guide 20, thereby preventing the needle 22 frombeing inserted too far into the reservoir 14. The bore 24 of the guide20 is curved to help align the needle 22 with the fill port 16. Todispense the drug, the healthcare provider depresses a plunger 26 of thesyringe 12.

SUMMARY

In accordance with a first exemplary aspect, a system for filling anon-body injector using a prefilled syringe may include an on-bodyinjector. The on-body injector may include a housing having an interiorsurface defining an interior cavity and an exterior surface. The on-bodyinjector may further include a reservoir disposed within the interiorcavity and configured to receive a volume of a drug. A drug deliverymember may be in fluid communication with the reservoir, and configuredto extend beyond the exterior surface of the housing through an openingin the housing. A fill port may include an inlet disposed on theexterior surface of the housing and may be in fluid communication withthe reservoir. The system may include a needle cover attached to aportion of the exterior surface of the housing and may cover the openingand the fill port. A guide of the needle cover may be coaxially alignedwith the fill port and may have an interior surface that defines a bore.The system may include a prefilled syringe having a barrel with a distalend and a barrel reservoir containing a volume of a drug. A needle ofthe prefilled syringe may be in fluid communication with the barrelreservoir and may be disposed at the distal end of the barrel. Anadapter may be attached to the distal end of the barrel and may surrounda portion of the needle. The adapter may be configured to mechanicallycouple to the guide of the needle cover when the adapter is positionedinside the bore of the guide.

In accordance with a second exemplary aspect, a system for filling anon-body injector using a prefilled syringe may include an on-bodyinjector. The on-body injector may include a housing having an interiorsurface defining an interior cavity and an exterior surface. The on-bodyinjector may further include a reservoir disposed within the interiorcavity and configured to receive a volume of a drug. A drug deliverymember may be in fluid communication with the reservoir, and configuredto extend beyond the exterior surface of the housing through an openingin the housing. A fill port may include an inlet disposed on theexterior surface of the housing and may be in fluid communication withthe reservoir. The system may include a needle cover attached to aportion of the exterior surface of the housing and may cover the openingand the fill port. A guide of the needle cover may be coaxially alignedwith the fill port and may have an interior surface that defines atapered bore. The system may include a prefilled syringe having a barrelwith a distal end and a barrel reservoir containing a volume of a drug.A needle of the prefilled syringe may be in fluid communication with thebarrel reservoir and may be disposed at the distal end of the barrel. Anadapter may be attached to the distal end of the barrel and may surrounda portion of the needle. The adapter may have a tapered exterior surfacethat is complementary with the interior surface of the guide.

In accordance with a third exemplary aspect, a method of securing aprefilled syringe to an on-body injector for filling may includeinserting a needle of a prefilled syringe into a guide of a needle coverattached to an on-body injector, where the prefilled syringe may includean adapter attached to the syringe and configured to guide the needle ofthe prefilled syringe to a fill port of the on-body injector. Next, themethod may include inserting the needle into the fill port where thefill port may be in fluid communication with a reservoir of the on-bodyinjector. Then, the method may include coupling the adapter to the guideand dispensing a volume of a drug of the prefilled syringe into thereservoir of on-body injector.

In further accordance with any one or more of the foregoing first,second, or third aspects, a system for filling an on-body injectorand/or method a method of securing for filling an on-body injector mayfurther include any one or more of the following forms. In one form ofthe system, a tip of the needle of the prefilled syringe may bepositioned within the fill port when the prefilled syringe is insertedinto the bore of the guide.

In one form of the system, the interior surface of the guide may betapered, and the adapter may further include a tapered exterior surfacethat is substantially complementary with the tapered interior surface ofthe bore.

In one form of the system, the interior surface of the guide may bestraight-walled, and the adapter may further include a straight-walledexterior surface that is substantially complementary with thestraight-walled interior surface of the bore.

In one form of the system, the adapter may further include a compressiveO-ring disposed on the exterior surface of the adapter.

In one form of the system, the adapter may further include an exteriorsurface having a detent, and the guide may further include a grooveformed in the interior surface of the guide and configured to receivethe detent when the adapter is positioned inside the bore of the guide.

In one form of the system, the adapter may further include a male lockfitting and the guide may further include a female lock fittingconfigured to couple to the male lock fitting when the prefilled syringeis inserted into the bore of the guide.

In one form of the system, the adapter and the guide may be mechanicallycoupled by friction fit when the adapter is positioned inside the boreof the guide

In one form of the system, the guide may further include a shoulderhaving a surface disposed within the bore and the adapter may furtherinclude a nose having a surface that is substantially complementary withthe surface of the shoulder and is configured to mate with the surfaceof the shoulder when the guide and the adapter are mechanically coupled.

In one form of the system, the adapter may further include a female lockfitting and the guide may further include a male lock fitting configuredto couple to the female lock fitting when the adapter is inserted intothe bore of the guide.

In one form of the system, the guide may further include a detentdisposed on the interior surface of the guide, and wherein the adaptermay further include an exterior surface having a groove that isconfigured to receive the detent when the adapter is positioned insidethe bore of the guide.

In one form of the system, the adapter and the guide may magneticallycouple when the adapter is positioned inside the bore of the guide.

In one form of the method, coupling the adapter to the guide may includecoupling a female lock fitting of the guide with a male lock fitting ofthe adapter.

In one form of the method, dispensing a volume of the drug may beperformed after a detent of the adapter couples with a receiving grooveof the guide.

In one form of the method, coupling the adapter to the guide may includemoving a tapered surface of the adapter into a tapered bore of the guideso that the adapter is coupled to the guide by friction-fit.

In one form of the method, coupling the adapter to the guide may includefrictionally engaging a tapered exterior surface of the adapter with atapered interior surface of the guide.

In one form of the method, coupling the adapter to the guide may includecompressing an O-ring disposed about an exterior surface of the adapteragainst an interior surface of the guide to couple the adapter and theguide by friction fit.

In one form of the method, coupling the adapter to the guide may includepushing a protruded ring disposed on an exterior surface of the adapterinto a groove formed in an interior surface of the guide where thegroove may be shaped to receive the protruded ring and secure theadapter to the guide.

In one form, the method may include removing the needle from the fillport by decoupling the adapter from the guide.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates a perspective view of a known on-body injector andattached needle cover with an associated prefilled syringe that may beused to fill the on-body injector with a drug.

FIG. 2 illustrates a partial cross-sectional view of the needle cover,while the syringe is in position for filling the on-body injector ofFIG. 1.

FIG. 3 illustrates an exploded perspective view of a system for fillingan on-body injector using a prefilled syringe in accordance with theteachings of an exemplary arrangement of the present disclosure.

FIG. 4 illustrates a cross-sectional view of the system of FIG. 3 in acoupled position for filling the on-body injector.

FIG. 5 illustrates a partial exploded cross-sectional view of anexemplary syringe adapter and guide in accordance with the teachings ofthe present disclosure.

FIG. 6 illustrates a partial cross-sectional view of the syringe adapterand guide of FIG. 5 in a coupled position.

FIG. 7 illustrates a partial exploded cross-sectional view of anotherexemplary syringe adapter and guide in accordance with the teachings ofthe present disclosure.

FIG. 8 illustrates a partial cross-sectional view of the syringe adapterand guide of FIG. 7 in a coupled position.

FIG. 9 illustrates a partial exploded cross-sectional view of yetanother exemplary syringe adapter and guide in accordance with theteachings of the present disclosure.

FIG. 10 illustrates a partial cross-sectional view of the syringeadapter and guide of FIG. 9 in a coupled position.

FIG. 11 illustrates a partial exploded cross-sectional view of stillanother exemplary syringe adapter and guide in accordance with theteachings of the present disclosure.

FIG. 12 illustrates a partial cross-sectional view of the syringeadapter and guide of FIG. 11 in a coupled position.

DETAILED DESCRIPTION

Turning now to specific examples of the disclosure, FIGS. 3-4 illustratean improved system and method for securing a prefilled syringe to anon-body injector for filling.

Referring now to FIGS. 3-4, a filling system 100, or filling kit,includes an empty on-body injector 110, a prefilled syringe 112containing a drug, and a needle cover 114 attached to the on-bodyinjector 110. The on-body injector 110, which may also be referred toherein as the device, includes a housing 116 with an interior surface118 that defines an interior cavity 120, and an exterior surface 122. Areservoir 124 is disposed within the interior cavity 120 and isconfigured to receive a volume of the drug through a fill port 126. Thefill port 126 is in fluid communication with the reservoir 124 and hasan inlet 128 disposed on the exterior surface 122 of the housing 116. Adrug delivery member 130 is also disposed within the housing 116 and isin fluid communication with the reservoir 124. The drug delivery member130 is configured to extend beyond the exterior surface 122 of thehousing 116 through an opening 132 to deliver a drug to a patient, asdescribed further below.

The needle cover 114 is attached to a portion of the exterior surface122 of the housing 116 and can cover the opening 132 and the fill port126. The needle cover 114 includes a syringe guide 134 coaxially alignedwith an axis A-A of the fill port 126 to guide and secure the prefilledsyringe 112 to the on-body injector 110 when filling the device 110. Theguide 134 includes an interior surface 136 that defines a bore 138.

The prefilled syringe 112 includes a barrel 140 having a distal end 142,a barrel reservoir 144 containing a volume of the drug, and a needle 146attached to the barrel 140 at the distal end 142 of the syringe 112. Theneedle 146 is in fluid communication with the barrel reservoir 144. Asyringe adapter 148 is configured to mechanically couple to the guide134 when the adapter 148 is positioned inside the bore 138 of the guide134. In the depicted version, the adapter 148 is attached to the distalend 142 of the barrel 140 and surrounds a portion of the needle 146,leaving a portion of the needle 146 exposed. The adapter 148 may beattached, or otherwise fixed or coupled, to the syringe barrel 140 by asnap-fitting, friction-fitting, and/or by threading. In other versions,the adapter 148 can be formed integrally with the syringe 112, such aswith the syringe barrel 144, for example. The syringe adapter 148 may beattached to the barrel 140 before or after the syringe 112 is filledwith the drug. The system 100 can be provided as a kit to a healthcareprovider or patient and includes the prefilled syringe 112 with theattached syringe adapter 148 and an empty on-body injector 110 with theattached needle cover 114.

In one method for filling the on-body injector 110, a user aligns theneedle 146 of the prefilled syringe 112 with the axis A-A of the fillport 126 and then inserts the needle into the guide 134 of the needlecover 114. The adapter 148 attached to the syringe barrel 140 guides theneedle 146 into a center of the bore 138 of the guide 134 and into thefill port 126 of the on-body injector 110. The user then inserts theneedle 146 into the fill port 126 and the adapter 148 becomesmechanically coupled to the guide 134. After the adapter 148 ismechanically coupled to the guide 134, the user depresses a plunger 113on the syringe 112 to dispense the drug into the reservoir 124 of theon-body injector 110. Once the reservoir 124 is filled to a desiredamount, the needle 146 may be removed from the fill port 126 bydecoupling the adapter 148 from the guide 134.

The adapter 148 and the guide 134 mechanically couple so that thesyringe 112 is secured to the device 110 before filling the on-bodyinjector 110 with the drug. In the example of FIGS. 3-4, the guide 134and the adapter 148 may mechanically couple by interference fit. Theadapter 148 has an exterior surface 150 that is substantiallycomplementary with the interior surface 136 of the guide 134. In thiscase, the exterior surface 150 of the adapter 148 and the interiorsurface 136 of the guide 134 are tapered. The adapter 148 has atruncated conical shape and the bore 138 is shaped to receive theconical shape of the adapter 148. To couple the adapter 148 to the guide134, the adapter 148 is inserted into the bore 138 of the guide 134until the tapered surface 150 of the adapter 148 and the tapered surface136 of the guide 134 meet and couple by friction. As used herein, theterm “substantially complementary” refers to a summation of two anglesthat approaches 90°, the summation typically being within ±10°, within±5⁰, and/or within ±2° of 90°. As used herein, two surfaces that aresubstantially complementary, substantially supplementary, or similarlyshaped may be referred to as “corresponding surfaces.” In some versions,the exterior surface 150 of the adapter 148 and the interior surface 136of the guide 134 can be disposed at an angle α (shown in FIG. 4)relative to the axis A-A. In some versions, the angle α can be in arange of approximately 1° to approximately 60°, or in a range ofapproximately 1° to approximately 45°, or in a range of approximately 1°to approximately 30°, or in a range of approximately 1° to approximately15°, or in a range of approximately 1° to approximately 5°, or in arange of approximately 5° to approximately 60°, or in a range ofapproximately 5° to approximately 45°, or in a range of approximately 5°to approximately 30°, or in a range of approximately 5° to approximately15°, or in a range of approximately 5° to approximately 10°, or in arange of approximately 15° to approximately 60°, or in a range ofapproximately 15° to approximately 45°, or in a range of approximately15° to approximately 30°, or in a range of approximately 15° toapproximately 20°, or any other angle larger or smaller than the anglesstated above depending on the specific application and desired outcome.In one version, the angle α can be approximately 0°, within appropriatetolerances based on the type of manufacturing utilized to manufacturer,form and/or finish the exterior surface 150 of the adapter 148 and theinterior surface 136 of the guide 134. In such a version, the surfaces150, 136 can be described as being straight-walled. In fact, based onthe type of manufacturing method used, when the angle α of the interiorsurface 136 of the guide 134 is disposed at an angle α of approximately0°, such an interior surface 136 can be described as “tapered” because amolding process, for example, may necessarily require some degree oftapering in the molding draft. As such, the term “tapered” as usedherein is intended to also cover those situations where the surface 150,136 are disposed at approximately 0° relative to the axis A-A.Additionally, in versions where the angle α is approximately 0°, theinterior surface 150 of the adapter 148 and the exterior surface 136 ofthe guide 134 can be approximately parallel to each other andapproximately parallel to the axis A-A. Finally, while the foregoing hasdescribed the exterior surface 150 of the adapter 148 and the interiorsurface 136 of the guide 134 as sharing the same angle α, in otherversions, these two surfaces 150, 136 can have different angles. Forexample, in one version, the interior surface 136 of the guide 134 canbe disposed at an angle α1 that is larger than an angle α2, at which theexterior surface 150 of the adapter 148 is disposed. In another version,the interior surface 136 of the guide 134 can be disposed at an angle α1that is smaller than an angle α2, at which the exterior surface 150 ofthe adapter 148 is disposed. In either of these situations, α1 and α2can fall inside or outside any of the ranges specific above for angle α.

As shown in the illustrated example of FIGS. 3-4, the guide 134 includesa wall 156 that extends outwardly from a portion of the exterior surface122 of the housing 116 (underside of the device 110). When the adapter148 and the guide 134 are mechanically coupled, a portion of the adapter148 may contact or rest on a portion of the guide wall 156, suspendingthe needle 146 within the fill port 126 and limiting axial displacementof the needle 146 into the on-body injector 110. As shown best in FIG.3, the adapter 148 has a nose 158 at the distal end 142 of the syringe112. The nose 158 may have a surface 160 that corresponds to a surface166 of an interior shelf or shoulder 162 of the guide 134. As thesurfaces make contact, the surface 160 of the nose 158 couples to thesurface 166 of the shoulder 162, the shoulder 162 stopping the needle146 from moving further into the fill port 126. The height of the guidewall 156 and placement of the adapter 148 on the syringe 112, andtherefore the length of the exposed needle 146, are configured so that atip 164 of the needle 146 reaches a predetermined position within theon-body injector 110 for optimal delivery of the drug into the reservoir124. The guide 134 and corresponding adapter 148 reduce the risk ofinserting the needle 146 too far into the on-body injector 110 andpuncturing a wall of the reservoir 124 and/or blocking the tip 164 ofthe needle 146 from delivering the drug. The system is not limited tothe syringe adapter 148 and guide 134 illustrated in FIGS. 3-4, and mayinclude a syringe adapter and guide pair having a configuration thatadequately positions the needle 146 in the on-body injector 110 fordelivery.

The system 100 illustrated and described herein advantageouslyfacilitates the process of filling an on-body injector 100 with aprefilled syringe 112. The tapered shape of the adapter 148 and taperedshape of the bore 138 of the guide 134 helps align the needle 146 withthe axis A-A of the fill port 126 and guides the syringe 112 intoposition. The corresponding surfaces (e.g. exterior surface 150 of theadapter 148 and interior surface 135 of the guide 134) provide a bufferbetween the delicate needle 146 and the hard surface of the guide 134.The syringe adapter 148 and guide 134 facilitate accurate and suitablepositioning of the needle 146 for filling. Further, the mechanicalcoupling between the adapter 148 and the guide 134 stabilizes thesyringe 112 relative to the on-body injector 110 during filling suchthat a healthcare provider or user does not have to hold the on-bodyinjector 110 in alignment with the syringe 112 when dispensing the druginto the reservoir 124. In other words, once the adapter 148 is coupledto the guide 134, the needle 146 is secured in place for filling andremains aligned with axis A-A of the fill port 126, at the appropriatedepth dictated by contact between surfaces 160 and 166.

The syringe adapter and guide configuration is not limited to theexample shown in FIGS. 3-4. The adapter and guide may mechanicallycouple by other coupling or locking methods such that when the adapterand the guide are coupled, the syringe needle 146 remains aligned withthe fill port 126 until the adapter 148 and guide 134 are pulled apartor otherwise decoupled. An audible clicking noise may be incorporatedinto the coupling mechanism to alert a user that the adapter 146 iscoupled to the guide 134 and ready for filling.

In FIGS. 5-10, various alternative configurations of syringe adaptersand guides are illustrated in both an uncoupled position and a coupledposition. While the present disclosure describes and discusses variousadapters and guides having different features, it is contemplated thatthe different features can be combined in any manner or fashion toachieve desired results. For example, the present disclosurecontemplated that the adapter and guide in FIGS. 3-4 can be modified toinclude any or all of the features of any of FIGS. 5-10 and/or elsewherediscussed herein. The present disclosure contemplated that the adapterand guide in FIGS. 5-6 can be modified to include any or all of thefeatures of any of FIGS. 3-4 and 7-10 and/or elsewhere discussed herein.The present disclosure contemplated that the adapter and guide in FIGS.7-8 can be modified to include any or all of the features of any ofFIGS. 3-6 and 9-10 and/or elsewhere discussed herein. The presentdisclosure contemplated that the adapter and guide in FIGS. 9-10 can bemodified to include any or all of the features of any of FIGS. 3-8and/or elsewhere discussed herein. Thus, while the following featurescan be considered as independent alternatives, they can also becomplementary features, in that any given adapter and guide pair withinthe scope of the present disclosure can include any combination offeatures taken from FIGS. 3-10 and/or elsewhere discussed herein.

In FIGS. 5-6, a syringe adapter and guide pair 200 includes an adapter202 having a compressive O-ring 206 disposed within a groove 210 formedin a conical exterior surface 208 of the adapter 202. A guide 204 alsoincludes a compressive O-ring 214 disposed within a groove 216 formed ina complementary conical interior surface 218 of the guide 204. As theadapter 202 is inserted within a bore 220 of the guide 204, the O-ring206 of the adapter 202 may compress against the interior surface 218 andthe O-ring 214 of the guide 204. The adapter 202 and guide 204mechanically couple when the O-ring 206 of the adapter 202 passes theO-ring 214 of the guide 204 as shown in FIG. 6. The adapter 202 iscoupled to the guide 204 by friction fit. In FIG. 6, the O-rings 206,214 are illustrated as out of contact when the adapter 202 is coupled tothe guide 204, but in other versions, the O-rings 206, 214 can be incontact when the adapter 202 and guide 204 are coupled. To decouple theadapter 202 and the guide 204, the adapter 202 may be pulled away fromthe guide 206, thereby compressing the O-rings 206, 214 to allow theadapter 202 is slide out of the bore 220. While two O-rings 206, 214 areillustrated in FIGS. 5-6, one O-ring disposed on either the interiorsurface 218 of the guide 204 or the exterior surface 208 of the adapter202 may sufficiently couple the syringe adapter and guide pair 200 byfriction fit.

In another exemplary configuration, a syringe adapter and guide pair 300in FIGS. 7-8 includes an adapter 302 with a detent 306 protruding from aconical exterior surface 308 of the adapter 302. A guide 304 may have areceiving groove 314 formed in a complementary conical interior surface318 to receive the detent 306. To couple the adapter 302 and the guide304, the adapter 302 is pushed into a bore 320 of the guide 304 untilthe detent 306 snaps into the receiving groove 314 formed in theinterior surface 318 of the guide 304. Alternatively, the interiorsurface 318 of the guide 304 may have a detent (not illustrated) and theexterior surface 308 of the adapter 302 may include a groove (notillustrated) configured to receive the detent when the adapter 302 isinserted into the guide 304. The detent may be a hooking mechanism or itmay be an annular ring or ridge that is configured to mate with areceiving groove. For the sake of clarity only, FIG. 8 illustrates acertain spacing or gap between the adapter 302 and guide 304 when thetwo are coupled. In some versions, the adapter 302 and guide 304maintain a close snug fit, without spacing, when coupled together.Moreover, as suggested above, in some versions, the exterior surface 308of the adapter 302 and the interior surface 318 of the guide 304 canform a friction tight interference fit when the adapter 302 and guide304 are coupled. This interference friction fit can assist the detent306 with the coupling of these components together.

In yet another example, a syringe adapter and guide pair 400 illustratedin FIGS. 9-10 includes a protruded ring 406 that may extend from asurface 408 of a nose 426 of an adapter 402. A groove 414 is formed in ashoulder 428 of a guide 404 and is configured to receive the protrudedring 406. To couple, the adapter 402 is pushed into the guide 404 untilthe protruded ring 406 snaps into the groove 414. In otherconfigurations, the syringe adapter and guide may mechanically couple bymating a male lock fitting with a corresponding female lock fitting. Forexample, the coupling mechanism of an adapter and guide may be aconventional bayonet connector. The adapter may include a male fittinghaving one or more radial pins and the guide may include a femalereceptor with corresponding L-shaped slots to receive the radial pins.When the adapter is inserted into a bore of the guide, the adapter (i.e.the syringe) may be slightly rotated so that the one or more radial pinsmay be inserted into the L-shaped slots and locked into place. Again,for the sake of clarity only, FIG. 10 illustrates a certain spacing orgap between the adapter 402 and guide 404 when the two are coupled. Insome versions, the adapter 402 and guide 404 maintain a close snug fit,without spacing, when coupled together. Moreover, as suggested above, insome versions, the adapter 402 and the guide 404 can form a frictiontight interference fit when the adapter 402 and guide 404 are coupled.This interference friction fit can assist with coupling these componentstogether.

The syringe adapter and guide of any of the foregoing versions may bemanufactured using certain materials. For example, certain materials maybe used that enhance the mechanical engagement between the correspondingsurfaces so that the adapter and guide couple when the adapter is pushedinto the guide. In some versions, either or both of the syringe adapterand guide may be a rubber material, a plastic material, a resilientelastomer material, a cork material, or any other suitable material orcombination of materials including those having resilient andnon-resilient properties. In some versions, one or more of the adapterand guide may include a material that magnetically couples to a materialof the other. For example, in one version, one of the guide and theadapter can include a magnetic insert embedded within a plastic materialand the other of the guide and adapter can have a magnet such that whenthe adapter is inserted into the guide, they become magneticallycoupled.

As one example, it should be appreciated that in some versions such asthat described in reference to FIGS. 3-4, the guide 134 could be made ofa hard plastic material and the adapter 146 could be made of or coatedwith a resilient material such that when the adapter 146 is insertedinto the guide 134, the resilient material compresses to exert anoutward radial force against the guide 134 to further retain the adapter146 in the guide 134. Other variations are possible.

As illustrated in FIGS. 11-12, an adapter 502 may be a moldablematerial, such as a foam, that compresses when inserted into a guide504. The moldable material partially expands to fill an interior spacedefined by an interior surface 518 of the guide 504, thereby keeping theadapter in place. In other examples, the exterior surface of the adapterand the interior surface of the guide may be treated with a coatingand/or other additive to enhance the frictional forces between thesurfaces. The syringe adapter and guide may be a single material or acombination of materials. For example, the adapter may include amagnetic strip or coating to position and secure the adapter in placerelative to the guide.

The exemplary adapter and guide configurations as described andillustrated in FIGS. 3-13 are not limited to the use of the specificon-body injector 110 illustrated in FIG. 4, and may be used with asuitable empty drug delivery device. Referring back to FIG. 4, theexemplary on-body injector 110 will be described in more detail.

The device 110 adheres to the skin of a patient, most likely, but notexclusively, after being placed there by healthcare personnel associatedwith the procedure. The device 110 automatically injects a drug deliverydevice 130 from an interior cavity 120 (sealed by the needle cover 114)defined by the housing 116 into the patient to define an injection site.The device 110 automatically actuates a drug supply to deliver a volumeof a drug to the patient through an injection site as a single bolusaccording to the configuration of a controller 170.

The drug delivery device 130 includes a needle 172 with a pointed end174. The needle 172 has a retracted state wherein the pointed end 174 ofthe needle is withdrawn inside the cavity 120 defined by the housing116, as shown in FIG. 4. The needle 172 also has a deployed statewherein the pointed end 174 of the needle 172 projects from the cavity120 beyond the exterior surface 122 of the housing 116 into theinjection site of the patient. The needle 172 may be used in conjunctionwith a catheter 178, the needle 172 being used to insert the catheter178 into the patient through the injection site, and the drug passingthrough the catheter 178 into the patient during administration. Thedevice 110 includes an injector 180 that moves the needle 172 betweenthe retracted and deployed states.

The controller 170 is coupled to the injector 180 and the drug supply.The controller 170 is programmed to control the injector 180 and thedrug supply, and may operate the injector 180 to move the needle 172 andthe drug supply to deliver the volume of the drug. The controller 170 isdisposed within the sealed cavity 120 defined within the disposablehousing 116 and programmed prior to being disposed within the sealedcavity 120. Thus, once the controller 170 is disposed in the cavity 120and the housing 116 is sealed, the controller 170 may not bereprogrammed.

The housing 116 may have an aperture or opening 132 formed therein topermit the needle 172 (and catheter 178) to pass therethrough. Accordingto certain embodiments, the aperture 132 may be unobstructed such thatthere is no impediment or obstacle to the movement of the needle 172(and catheter 178) through the opening 132. However, to better maintainthe sterility of the needle 172 and the container closure integrity(CCI) of the device 110, a septum may be disposed in or over theaperture 132, or within the cavity 120 defined by the housing 116 so asto overlie the opening 132. In one variant, the septum may be made ofrubber. The septum is disposed between the needle and the needle cover114 in the retracted state. In the deployed state, at least a portion ofthe needle 172 will emerge from the cavity 120 through the septum. Assuch, the septum is always present as a barrier between the interiorcavity 120 and the external environment.

According to the illustrated embodiment, the drug supply may include apump 182 and a reservoir 124. According to an embodiment of the presentdisclosure, the reservoir 124 and pump 182 may be defined in part by acombination of a rigid-walled cylinder and plunger 184 fitted to movealong a longitudinal axis of the cylinder. The reservoir 124 may be aflexible pouch. Further, the fill port 126 is in fluid communicationwith the reservoir 124 and has an inlet 128 disposed on the exteriorsurface 122 of the housing 116. The fill port 126 may also include acover disposed in the inlet 128 to close the fill port 126. An outlet186 of the fill port 126 is fluidly connected to the reservoir 124. Oneor more filters may be disposed between the inlet 128 and the outlet 186to limit the passage of air or particulate matter into the reservoir 124along with the drug.

The above description describes various systems and methods for fillinga drug delivery device. It should be clear that the system, drugdelivery device, syringe, or methods can further comprise use of amedicament listed below with the caveat that the following list shouldneither be considered to be all inclusive nor limiting.

For example, the drug delivery device or more specifically the reservoirof the device may be filled with colony stimulating factors, such asgranulocyte colony-stimulating factor (G-CSF). Such G-CSF agentsinclude, but are not limited to, Neupogen® (filgrastim) and Neulasta®(pegfilgrastim). In various other embodiments, the drug delivery devicemay be used with various pharmaceutical products, such as anerythropoiesis stimulating agent (ESA), which may be in a liquid or alyophilized form. An ESA is any molecule that stimulates erythropoiesis,such as Epogen® (epoetin alfa), Aranesp® (darbepoetin alfa), Dynepo®(epoetin delta), Mircera® (methyoxy polyethylene glycol-epoetin beta),Hematide®, MRK-2578, INS-22, Retacrit® (epoetin zeta), Neorecormon®(epoetin beta), Silapo® (epoetin zeta), Binocrit® (epoetin alfa),epoetin alfa Hexal, Abseamed® (epoetin alfa), Ratioepo® (epoetin theta),Eporatio® (epoetin theta), Biopoin® (epoetin theta), epoetin alfa,epoetin beta, epoetin zeta, epoetin theta, and epoetin delta, as well asthe molecules or variants or analogs thereof as disclosed in thefollowing patents or patent applications, each of which is hereinincorporated by reference in its entirety: U.S. Pat. Nos. 4,703,008;5,441,868; 5,547,933; 5,618,698; 5,621,080; 5,756,349; 5,767,078;5,773,569; 5,955,422; 5,986,047; 6,583,272; 7,084,245; and 7,271,689;and PCT Publication Nos. WO 91/05867; WO 95/05465; WO 96/40772; WO00/24893; WO 01/81405; and WO 2007/136752.

An ESA can be an erythropoiesis stimulating protein. As used herein,“erythropoiesis stimulating protein” means any protein that directly orindirectly causes activation of the erythropoietin receptor, forexample, by binding to and causing dimerization of the receptor.Erythropoiesis stimulating proteins include erythropoietin and variants,analogs, or derivatives thereof that bind to and activate erythropoietinreceptor; antibodies that bind to erythropoietin receptor and activatethe receptor; or peptides that bind to and activate erythropoietinreceptor. Erythropoiesis stimulating proteins include, but are notlimited to, epoetin alfa, epoetin beta, epoetin delta, epoetin omega,epoetin iota, epoetin zeta, and analogs thereof, pegylatederythropoietin, carbamylated erythropoietin, mimetic peptides (includingEMP1/hematide), and mimetic antibodies. Exemplary erythropoiesisstimulating proteins include erythropoietin, darbepoetin, erythropoietinagonist variants, and peptides or antibodies that bind and activateerythropoietin receptor (and include compounds reported in U.S.Publication Nos. 2003/0215444 and 2006/0040858, the disclosures of eachof which is incorporated herein by reference in its entirety) as well aserythropoietin molecules or variants or analogs thereof as disclosed inthe following patents or patent applications, which are each hereinincorporated by reference in its entirety: U.S. Pat. Nos. 4,703,008;5,441,868; 5,547,933; 5,618,698; 5,621,080; 5,756,349; 5,767,078;5,773,569; 5,955,422; 5,830,851; 5,856,298; 5,986,047; 6,030,086;6,310,078; 6,391,633; 6,583,272; 6,586,398; 6,900,292; 6,750,369;7,030,226; 7,084,245; and 7,217,689; U.S. Publication Nos. 2002/0155998;2003/0077753; 2003/0082749; 2003/0143202; 2004/0009902; 2004/0071694;2004/0091961; 2004/0143857; 2004/0157293; 2004/0175379; 2004/0175824;2004/0229318; 2004/0248815; 2004/0266690; 2005/0019914; 2005/0026834;2005/0096461; 2005/0107297; 2005/0107591; 2005/0124045; 2005/0124564;2005/0137329; 2005/0142642; 2005/0143292; 2005/0153879; 2005/0158822;2005/0158832; 2005/0170457; 2005/0181359; 2005/0181482; 2005/0192211;2005/0202538; 2005/0227289; 2005/0244409; 2006/0088906; and2006/0111279; and PCT Publication Nos. WO 91/05867; WO 95/05465; WO99/66054; WO 00/24893; WO 01/81405; WO 00/61637; WO 01/36489; WO02/014356; WO 02/19963; WO 02/20034; WO 02/49673; WO 02/085940; WO03/029291; WO 2003/055526; WO 2003/084477; WO 2003/094858; WO2004/002417; WO 2004/002424; WO 2004/009627; WO 2004/024761; WO2004/033651; WO 2004/035603; WO 2004/043382; WO 2004/101600; WO2004/101606; WO 2004/101611; WO 2004/106373; WO 2004/018667; WO2005/001025; WO 2005/001136; WO 2005/021579; WO 2005/025606; WO2005/032460; WO 2005/051327; WO 2005/063808; WO 2005/063809; WO2005/070451; WO 2005/081687; WO 2005/084711; WO 2005/103076; WO2005/100403; WO 2005/092369; WO 2006/50959; WO 2006/02646; and WO2006/29094.

Examples of other pharmaceutical products for use with the device mayinclude, but are not limited to, antibodies such as Vectibix®(panitumumab), Xgeva™ (denosumab) and Prolia™ (denosamab); otherbiological agents such as Enbrel® (etanercept, TNF-receptor/Fc fusionprotein, TNF blocker), Neulasta® (pegfilgrastim, pegylated filgastrim,pegylated G-CSF, pegylated hu-Met-G-CSF), Neupogen® (filgrastim, G-CSF,hu-MetG-CSF), and Nplate® (romiplostim); small molecule drugs such asSensipar® (cinacalcet). The device may also be used with a therapeuticantibody, a polypeptide, a protein or other chemical, such as an iron,for example, ferumoxytol, iron dextrans, ferric glyconate, and ironsucrose. The pharmaceutical product may be in liquid form, orreconstituted from lyophilized form.

Among particular illustrative proteins are the specific proteins setforth below, including fusions, fragments, analogs, variants orderivatives thereof:

OPGL specific antibodies, peptibodies, and related proteins, and thelike (also referred to as RANKL specific antibodies, peptibodies and thelike), including fully humanized and human OPGL specific antibodies,particularly fully humanized monoclonal antibodies, including but notlimited to the antibodies described in PCT Publication No. WO 03/002713,which is incorporated herein in its entirety as to OPGL specificantibodies and antibody related proteins, particularly those having thesequences set forth therein, particularly, but not limited to, thosedenoted therein: 9H7; 18B2; 2D8; 2E11; 16E1; and 22B3, including theOPGL specific antibodies having either the light chain of SEQ ID NO:2 asset forth therein in FIG. 2 and/or the heavy chain of SEQ ID NO:4, asset forth therein in FIG. 4, each of which is individually andspecifically incorporated by reference herein in its entirety fully asdisclosed in the foregoing publication;

Myostatin binding proteins, peptibodies, and related proteins, and thelike, including myostatin specific peptibodies, particularly thosedescribed in U.S. Publication No. 2004/0181033 and PCT Publication No.WO 2004/058988, which are incorporated by reference herein in theirentirety particularly in parts pertinent to myostatin specificpeptibodies, including but not limited to peptibodies of the mTN8-19family, including those of SEQ ID NOS:305-351, including TN8-19-1through TN8-19-40, TN8-19 con1 and TN8-19 con2; peptibodies of the mL2family of SEQ ID NOS:357-383; the mL15 family of SEQ ID NOS:384-409; themL17 family of SEQ ID NOS:410-438; the mL20 family of SEQ IDNOS:439-446; the mL21 family of SEQ ID NOS:447-452; the mL24 family ofSEQ ID NOS:453-454; and those of SEQ ID NOS:615-631, each of which isindividually and specifically incorporated by reference herein in theirentirety fully as disclosed in the foregoing publication;

IL-4 receptor specific antibodies, peptibodies, and related proteins,and the like, particularly those that inhibit activities mediated bybinding of IL-4 and/or IL-13 to the receptor, including those describedin PCT Publication No. WO 2005/047331 or PCT Application No.PCT/US2004/37242 and in U.S. Publication No. 2005/112694, which areincorporated herein by reference in their entirety particularly in partspertinent to IL-4 receptor specific antibodies, particularly suchantibodies as are described therein, particularly, and withoutlimitation, those designated therein: L1H1; L1H2; L1H3; L1H4; L1H5;L1H6; L1H7; L1H8; L1H9; L1H10; L1H11; L2H1; L2H2; L2H3; L2H4; L2H5;L2H6; L2H7; L2H8; L2H9; L2H10; L2H11; L2H12; L2H13; L2H14; L3H1; L4H1;L5H1; L6H1, each of which is individually and specifically incorporatedby reference herein in its entirety fully as disclosed in the foregoingpublication;

Interleukin 1-receptor 1 (“IL1-R1”) specific antibodies, peptibodies,and related proteins, and the like, including but not limited to thosedescribed in U.S. Publication No. 2004/097712, which is incorporatedherein by reference in its entirety in parts pertinent to IL1-R1specific binding proteins, monoclonal antibodies in particular,especially, without limitation, those designated therein: 15CA, 26F5,27F2, 24E12, and 10H7, each of which is individually and specificallyincorporated by reference herein in its entirety fully as disclosed inthe aforementioned publication;

Ang2 specific antibodies, peptibodies, and related proteins, and thelike, including but not limited to those described in PCT PublicationNo. WO 03/057134 and U.S. Publication No. 2003/0229023, each of which isincorporated herein by reference in its entirety particularly in partspertinent to Ang2 specific antibodies and peptibodies and the like,especially those of sequences described therein and including but notlimited to: L1(N); L1(N) WT; L1(N) 1K WT; 2xL1(N); 2xL1(N) WT; Con4 (N),Con4 (N) 1K WT, 2xCon4 (N) 1K; L1C; L1C 1K; 2xL1C; Con4C; Con4C 1K;2xCon4C 1K; Con4-L1 (N); Con4-L1C; TN-12-9 (N); C17 (N); TN8-8(N);TN8-14 (N); Con 1 (N), also including anti-Ang 2 antibodies andformulations such as those described in PCT Publication No. WO2003/030833 which is incorporated herein by reference in its entirety asto the same, particularly Ab526; Ab528; Ab531; Ab533; Ab535; Ab536;Ab537; Ab540; Ab543; Ab544; Ab545; Ab546; A551; Ab553; Ab555; Ab558;Ab559; Ab565; AbF1AbFD; AbFE; AbFJ; AbFK; AbG1D4; AbGC1E8; AbH1C12;AblA1; AbIF; AbIK, AbIP; and AbIP, in their various permutations asdescribed therein, each of which is individually and specificallyincorporated by reference herein in its entirety fully as disclosed inthe foregoing publication;

NGF specific antibodies, peptibodies, and related proteins, and the likeincluding, in particular, but not limited to those described in U.S.Publication No. 2005/0074821 and U.S. Pat. No. 6,919,426, which areincorporated herein by reference in their entirety particularly as toNGF-specific antibodies and related proteins in this regard, includingin particular, but not limited to, the NGF-specific antibodies thereindesignated 4D4, 4G6, 6H9, 7H2, 14D10 and 14D11, each of which isindividually and specifically incorporated by reference herein in itsentirety fully as disclosed in the foregoing publication;

CD22 specific antibodies, peptibodies, and related proteins, and thelike, such as those described in U.S. Pat. No. 5,789,554, which isincorporated herein by reference in its entirety as to CD22 specificantibodies and related proteins, particularly human CD22 specificantibodies, such as but not limited to humanized and fully humanantibodies, including but not limited to humanized and fully humanmonoclonal antibodies, particularly including but not limited to humanCD22 specific IgG antibodies, such as, for instance, a dimer of ahuman-mouse monoclonal hLL2 gamma-chain disulfide linked to ahuman-mouse monoclonal hLL2 kappa-chain, including, but limited to, forexample, the human CD22 specific fully humanized antibody inEpratuzumab, CAS registry number 501423-23-0;

IGF-1 receptor specific antibodies, peptibodies, and related proteins,and the like, such as those described in PCT Publication No. WO06/069202, which is incorporated herein by reference in its entirety asto IGF-1 receptor specific antibodies and related proteins, includingbut not limited to the IGF-1 specific antibodies therein designatedL1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11,L12H12, L13H13, L14H14, L15H15, L16H16, L17H17, L18H18, L19H19, L20H20,L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, L27H27, L28H28, L29H29,L30H30, L31H31, L32H32, L33H33, L34H34, L35H35, L36H36, L37H37, L38H38,L39H39, L40H40, L41H41, L42H42, L43H43, L44H44, L45H45, L46H46, L47H47,L48H48, L49H49, L50H50, L51H51, L52H52, and IGF-1R-binding fragments andderivatives thereof, each of which is individually and specificallyincorporated by reference herein in its entirety fully as disclosed inthe foregoing publication;

Also among non-limiting examples of anti-IGF-1R antibodies for use inthe methods and compositions of the present invention are each and allof those described in:

(i) U.S. Publication No. 2006/0040358 (published Feb. 23, 2006),2005/0008642 (published Jan. 13, 2005), 2004/0228859 (published Nov. 18,2004), including but not limited to, for instance, antibody 1A (DSMZDeposit No. DSM ACC 2586), antibody 8 (DSMZ Deposit No. DSM ACC 2589),antibody 23 (DSMZ Deposit No. DSM ACC 2588) and antibody 18 as describedtherein;

(ii) PCT Publication No. WO 06/138729 (published Dec. 28, 2006) and WO05/016970 (published Feb. 24, 2005), and Lu et al. (2004), J. Biol.Chem. 279:2856-2865, including but not limited to antibodies 2F8, A12,and IMC-A12 as described therein;

(iii) PCT Publication No. WO 07/012614 (published Feb. 1, 2007), WO07/000328 (published Jan. 4, 2007), WO 06/013472 (published Feb. 9,2006), WO 05/058967 (published Jun. 30, 2005), and WO 03/059951(published Jul. 24, 2003);

(iv) U.S. Publication No. 2005/0084906 (published Apr. 21, 2005),including but not limited to antibody 7C10, chimaeric antibody C7C10,antibody h7C10, antibody 7H2M, chimaeric antibody *7C10, antibody GM607, humanized antibody 7C10 version 1, humanized antibody 7C10 version2, humanized antibody 7C10 version 3, and antibody 7H2HM, as describedtherein;

(v) U.S. Publication Nos. 2005/0249728 (published Nov. 10, 2005),2005/0186203 (published Aug. 25, 2005), 2004/0265307 (published Dec. 30,2004), and 2003/0235582 (published Dec. 25, 2003) and Maloney et al.(2003), Cancer Res. 63:5073-5083, including but not limited to antibodyEM164, resurfaced EM164, humanized EM164, huEM164 v1.0, huEM164 v1.1,huEM164 v1.2, and huEM164 v1.3 as described therein;

(vi) U.S. Pat. No. 7,037,498 (issued May 2, 2006), U.S. Publication Nos.2005/0244408 (published Nov. 30, 2005) and 2004/0086503 (published May6, 2004), and Cohen, et al. (2005), Clinical Cancer Res. 11:2063-2073,e.g., antibody CP-751,871, including but not limited to each of theantibodies produced by the hybridomas having the ATCC accession numbersPTA-2792, PTA-2788, PTA-2790, PTA-2791, PTA-2789, PTA-2793, andantibodies 2.12.1, 2.13.2, 2.14.3, 3.1.1, 4.9.2, and 4.17.3, asdescribed therein;

(vii) U.S. Publication Nos. 2005/0136063 (published Jun. 23, 2005) and2004/0018191 (published Jan. 29, 2004), including but not limited toantibody 19D12 and an antibody comprising a heavy chain encoded by apolynucleotide in plasmid 15H12/19D12 HCA (y4), deposited at the ATCCunder number PTA-5214, and a light chain encoded by a polynucleotide inplasmid 15H12/19D12 LCF (K), deposited at the ATCC under numberPTA-5220, as described therein; and

(viii) U.S. Publication No. 2004/0202655 (published Oct. 14, 2004),including but not limited to antibodies PINT-6A1, PINT-7A2, PINT-7A4,PINT-7A5, PINT-7A6, PINT-8A1, PINT-9A2, PINT-11A1, PINT-11A2, PINT-11A3,PINT-11A4, PINT-11A5, PINT-11A7, PINT-11A12, PINT-12A1, PINT-12A2,PINT-12A3, PINT-12A4, and PINT-12A5, as described therein; each and allof which are herein incorporated by reference in their entireties,particularly as to the aforementioned antibodies, peptibodies, andrelated proteins and the like that target IGF-1 receptors;

B-7 related protein 1 specific antibodies, peptibodies, related proteinsand the like (“B7RP-1,” also is referred to in the literature as B7H2,ICOSL, B7h, and CD275), particularly B7RP-specific fully humanmonoclonal IgG2 antibodies, particularly fully human IgG2 monoclonalantibody that binds an epitope in the first immunoglobulin-like domainof B7RP-1, especially those that inhibit the interaction of B7RP-1 withits natural receptor, ICOS, on activated T cells in particular,especially, in all of the foregoing regards, those disclosed in U.S.Publication No. 2008/0166352 and PCT Publication No. WO 07/011941, whichare incorporated herein by reference in their entireties as to suchantibodies and related proteins, including but not limited to antibodiesdesignated therein as follow: 16H (having light chain variable and heavychain variable sequences SEQ ID NO:1 and SEQ ID NO:7 respectivelytherein); 5D (having light chain variable and heavy chain variablesequences SEQ ID NO:2 and SEQ ID NO:9 respectively therein); 2H (havinglight chain variable and heavy chain variable sequences SEQ ID NO:3 andSEQ ID NO:10 respectively therein); 43H (having light chain variable andheavy chain variable sequences SEQ ID NO:6 and SEQ ID NO:14 respectivelytherein); 41H (having light chain variable and heavy chain variablesequences SEQ ID NO:5 and SEQ ID NO:13 respectively therein); and 15H(having light chain variable and heavy chain variable sequences SEQ IDNO:4 and SEQ ID NO:12 respectively therein), each of which isindividually and specifically incorporated by reference herein in itsentirety fully as disclosed in the foregoing publication;

IL-15 specific antibodies, peptibodies, and related proteins, and thelike, such as, in particular, humanized monoclonal antibodies,particularly antibodies such as those disclosed in U.S. Publication Nos.2003/0138421; 2003/023586; and 2004/0071702; and U.S. Pat. No.7,153,507, each of which is incorporated herein by reference in itsentirety as to IL-15 specific antibodies and related proteins, includingpeptibodies, including particularly, for instance, but not limited to,HuMax IL-15 antibodies and related proteins, such as, for instance,146B7;

IFN gamma specific antibodies, peptibodies, and related proteins and thelike, especially human IFN gamma specific antibodies, particularly fullyhuman anti-IFN gamma antibodies, such as, for instance, those describedin U.S. Publication No. 2005/0004353, which is incorporated herein byreference in its entirety as to IFN gamma specific antibodies,particularly, for example, the antibodies therein designated 1118;1118*; 1119; 1121; and 1121*. The entire sequences of the heavy andlight chains of each of these antibodies, as well as the sequences oftheir heavy and light chain variable regions and complementaritydetermining regions, are each individually and specifically incorporatedby reference herein in its entirety fully as disclosed in the foregoingpublication and in Thakur et al. (1999), Mol. Immunol. 36:1107-1115. Inaddition, description of the properties of these antibodies provided inthe foregoing publication is also incorporated by reference herein inits entirety. Specific antibodies include those having the heavy chainof SEQ ID NO:17 and the light chain of SEQ ID NO:18; those having theheavy chain variable region of SEQ ID NO:6 and the light chain variableregion of SEQ ID NO:8; those having the heavy chain of SEQ ID NO:19 andthe light chain of SEQ ID NO:20; those having the heavy chain variableregion of SEQ ID NO:10 and the light chain variable region of SEQ IDNO:12; those having the heavy chain of SEQ ID NO:32 and the light chainof SEQ ID NO:20; those having the heavy chain variable region of SEQ IDNO:30 and the light chain variable region of SEQ ID NO:12; those havingthe heavy chain sequence of SEQ ID NO:21 and the light chain sequence ofSEQ ID NO:22; those having the heavy chain variable region of SEQ IDNO:14 and the light chain variable region of SEQ ID NO:16; those havingthe heavy chain of SEQ ID NO:21 and the light chain of SEQ ID NO:33; andthose having the heavy chain variable region of SEQ ID NO:14 and thelight chain variable region of SEQ ID NO:31, as disclosed in theforegoing publication. A specific antibody contemplated is antibody 1119as disclosed in the foregoing U.S. publication and having a completeheavy chain of SEQ ID NO:17 as disclosed therein and having a completelight chain of SEQ ID NO:18 as disclosed therein;

TALL-1 specific antibodies, peptibodies, and the related proteins, andthe like, and other TALL specific binding proteins, such as thosedescribed in U.S. Publication Nos. 2003/0195156 and 2006/0135431, eachof which is incorporated herein by reference in its entirety as toTALL-1 binding proteins, particularly the molecules of Tables 4 and 5B,each of which is individually and specifically incorporated by referenceherein in its entirety fully as disclosed in the foregoing publications;

Parathyroid hormone (“PTH”) specific antibodies, peptibodies, andrelated proteins, and the like, such as those described in U.S. Pat. No.6,756,480, which is incorporated herein by reference in its entirety,particularly in parts pertinent to proteins that bind PTH;

Thrombopoietin receptor (“TPO-R”) specific antibodies, peptibodies, andrelated proteins, and the like, such as those described in U.S. Pat. No.6,835,809, which is herein incorporated by reference in its entirety,particularly in parts pertinent to proteins that bind TPO-R;

Hepatocyte growth factor (“HGF”) specific antibodies, peptibodies, andrelated proteins, and the like, including those that target theHGF/SF:cMet axis (HGF/SF:c-Met), such as the fully human monoclonalantibodies that neutralize hepatocyte growth factor/scatter (HGF/SF)described in U.S. Publication No. 2005/0118643 and PCT Publication No.WO 2005/017107, huL2G7 described in U.S. Pat. No. 7,220,410 and OA-5d5described in U.S. Pat. Nos. 5,686,292 and 6,468,529 and in PCTPublication No. WO 96/38557, each of which is incorporated herein byreference in its entirety, particularly in parts pertinent to proteinsthat bind HGF;

TRAIL-R2 specific antibodies, peptibodies, related proteins and thelike, such as those described in U.S. Pat. No. 7,521,048, which isherein incorporated by reference in its entirety, particularly in partspertinent to proteins that bind TRAIL-R2;

Activin A specific antibodies, peptibodies, related proteins, and thelike, including but not limited to those described in U.S. PublicationNo. 2009/0234106, which is herein incorporated by reference in itsentirety, particularly in parts pertinent to proteins that bind ActivinA;

TGF-beta specific antibodies, peptibodies, related proteins, and thelike, including but not limited to those described in U.S. Pat. No.6,803,453 and U.S. Publication No. 2007/0110747, each of which is hereinincorporated by reference in its entirety, particularly in partspertinent to proteins that bind TGF-beta;

Amyloid-beta protein specific antibodies, peptibodies, related proteins,and the like, including but not limited to those described in PCTPublication No. WO 2006/081171, which is herein incorporated byreference in its entirety, particularly in parts pertinent to proteinsthat bind amyloid-beta proteins. One antibody contemplated is anantibody having a heavy chain variable region comprising SEQ ID NO:8 anda light chain variable region having SEQ ID NO:6 as disclosed in theforegoing publication;

c-Kit specific antibodies, peptibodies, related proteins, and the like,including but not limited to those described in U.S. Publication No.2007/0253951, which is incorporated herein by reference in its entirety,particularly in parts pertinent to proteins that bind c-Kit and/or otherstem cell factor receptors;

OX40L specific antibodies, peptibodies, related proteins, and the like,including but not limited to those described in U.S. Publication No.2006/0002929, which is incorporated herein by reference in its entirety,particularly in parts pertinent to proteins that bind OX40L and/or otherligands of the OX40 receptor; and

Other exemplary proteins, including Activase® (alteplase, tPA); Aranesp®(darbepoetin alfa); Epogen® (epoetin alfa, or erythropoietin); GLP-1,Avonex® (interferon beta-1a); Bexxar® (tositumomab, anti-CD22 monoclonalantibody); Betaseron® (interferon-beta); Campath® (alemtuzumab,anti-CD52 monoclonal antibody); Dynepo® (epoetin delta); Velcade®(bortezomib); MLN0002 (anti-α4ß7 mAb); MLN1202 (anti-CCR2 chemokinereceptor mAb); Enbrel® (etanercept, TNF-receptor/Fc fusion protein, TNFblocker); Eprex® (epoetin alfa); Erbitux® (cetuximab,anti-EGFR/HER1/c-ErbB-1); Genotropin® (somatropin, Human GrowthHormone); Herceptin® (trastuzumab, anti-HER2/neu (erbB2) receptor mAb);Humatrope® (somatropin, Human Growth Hormone); Humira® (adalimumab);insulin in solution; Infergen® (interferon alfacon-1); Natrecor®(nesiritide; recombinant human B-type natriuretic peptide (hBNP);Kineret® (anakinra); Leukine® (sargamostim, rhuGM-CSF); LymphoCide®(epratuzumab, anti-CD22 mAb); Benlysta™ (lymphostat B, belimumab,anti-BlyS mAb); Metalyse® (tenecteplase, t-PA analog); Mircera® (methoxypolyethylene glycol-epoetin beta); Mylotarg® (gemtuzumab ozogamicin);Raptiva® (efalizumab); Cimzia® (certolizumab pegol, CDP 870); Soliris™(eculizumab); pexelizumab (anti-C5 complement); Numax® (MEDI-524);Lucentis® (ranibizumab); Panorex® (17-1A, edrecolomab); Trabio®(lerdelimumab); TheraCim hR3 (nimotuzumab); Omnitarg (pertuzumab, 2C4);Osidem® (IDM-1); OvaRex® (B43.13); Nuvion® (visilizumab); cantuzumabmertansine (huC242-DM1); NeoRecormon® (epoetin beta); Neumega®(oprelvekin, human interleukin-11); Neulasta® (pegylated filgastrim,pegylated G-CSF, pegylated hu-Met-G-CSF); Neupogen® (filgrastim, G-CSF,hu-MetG-CSF); Orthoclone OKT3® (muromonab-CD3, anti-CD3 monoclonalantibody); Procrit® (epoetin alfa); Remicade® (infliximab, anti-TNFαmonoclonal antibody); Reopro® (abciximab, anti-GP IIb/IIia receptormonoclonal antibody); Actemra® (anti-IL6 Receptor mAb); Avastin®(bevacizumab), HuMax-CD4 (zanolimumab); Rituxan® (rituximab, anti-CD20mAb); Tarceva® (erlotinib); Roferon-A®-(interferon alfa-2a); Simulect®(basiliximab); Prexige® (lumiracoxib); Synagis® (palivizumab); 146B7-CHO (anti-IL15 antibody, see U.S. Pat. No. 7,153,507); Tysabri®(natalizumab, anti-α4integrin mAb); Valortim® (MDX-1303, anti-B.anthracis protective antigen mAb); ABthrax™; Vectibix® (panitumumab);Xolair® (omalizumab); ETI211 (anti-MRSA mAb); IL-1 trap (the Fc portionof human IgG1 and the extracellular domains of both IL-1 receptorcomponents (the Type I receptor and receptor accessory protein)); VEGFtrap (Ig domains of VEGFR1 fused to IgG1 Fc); Zenapax® (daclizumab);Zenapax® (daclizumab, anti-IL-2Ra mAb); Zevalin® (ibritumomab tiuxetan);Zetia® (ezetimibe); Orencia® (atacicept, TACI-Ig); anti-CD80 monoclonalantibody (galiximab); anti-CD23 mAb (lumiliximab); BR2-Fc (huBR3/huFcfusion protein, soluble BAFF antagonist); CNTO 148 (golimumab, anti-TNFαmAb); HGS-ETR1 (mapatumumab; human anti-TRAIL Receptor-1 mAb);HuMax-CD20 (ocrelizumab, anti-CD20 human mAb); HuMax-EGFR (zalutumumab);M200 (volociximab, anti-α5ß1 integrin mAb); MDX-010 (ipilimumab,anti-CTLA-4 mAb and VEGFR-1 (IMC-18F1); anti-BR3 mAb; anti-C. difficileToxin A and Toxin B C mAbs MDX-066 (CDA-1) and MDX-1388); anti-CD22dsFv-PE38 conjugates (CAT-3888 and CAT-8015); anti-CD25 mAb (HuMax-TAC);anti-CD3 mAb (NI-0401); adecatumumab; anti-CD30 mAb (MDX-060); MDX-1333(anti-IFNAR); anti-CD38 mAb (HuMax CD38); anti-CD40L mAb; anti-CriptomAb; anti-CTGF Idiopathic Pulmonary Fibrosis Phase I Fibrogen (FG-3019);anti-CTLA4 mAb; anti-eotaxin1 mAb (CAT-213); anti-FGF8 mAb;anti-ganglioside GD2 mAb; anti-ganglioside GM2 mAb; anti-GDF-8 human mAb(MYO-029); anti-GM-CSF Receptor mAb (CAM-3001); anti-HepC mAb (HuMaxHepC); anti-IFNα mAb (MEDI-545, MDX-1103); anti-IGF1R mAb; anti-IGF-1RmAb (HuMax-Inflam); anti-IL12 mAb (ABT-874); anti-IL12/1L23 mAb (CNTO1275); anti-IL13 mAb (CAT-354); anti-IL2Ra mAb (HuMax-TAC); anti-IL5Receptor mAb; anti-integrin receptors mAb (MDX-018, CNTO 95); anti-IP10Ulcerative Colitis mAb (MDX-1100); anti-LLY antibody; BMS-66513;anti-Mannose Receptor/hCGβ mAb (MDX-1307); anti-mesothelin dsFv-PE38conjugate (CAT-5001); anti-PD1mAb (MDX-1106 (ONO-4538)); anti-PDGFRαantibody (IMC-3G3); anti-TGFß mAb (GC-1008); anti-TRAIL Receptor-2 humanmAb (HGS-ETR2); anti-TWEAK mAb; anti-VEGFR/Flt-1 mAb; anti-ZP3 mAb(HuMax-ZP3); NVS Antibody #1; and NVS Antibody #2.

Also included can be a sclerostin antibody, such as but not limited toromosozumab, blosozumab, or BPS 804 (Novartis). Further included can betherapeutics such as rilotumumab, bixalomer, trebananib, ganitumab,conatumumab, motesanib diphosphate, brodalumab, vidupiprant,panitumumab, denosumab, NPLATE, PROLIA, VECTIBIX or XGEVA. Additionally,included in the device can be a monoclonal antibody (IgG) that bindshuman Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). Such PCSK9specific antibodies include, but are not limited to, Repatha®(evolocumab) and Praluent® (alirocumab), as well as molecules, variants,analogs or derivatives thereof as disclosed in the following patents orpatent applications, each of which is herein incorporated by referencein its entirety for all purposes: U.S. Pat. No. 8,030,547, U.S.Publication No. 2013/0064825, WO2008/057457, WO2008/057458,WO2008/057459, WO2008/063382, WO2008/133647, WO2009/100297,WO2009/100318, WO2011/037791, WO2011/053759, WO2011/053783,WO2008/125623, WO2011/072263, WO2009/055783, WO2012/0544438,WO2010/029513, WO2011/111007, WO2010/077854, WO2012/088313,WO2012/101251, WO2012/101252, WO2012/101253, WO2012/109530, andWO2001/031007.

Also included can be talimogene laherparepvec or another oncolytic HSVfor the treatment of melanoma or other cancers. Examples of oncolyticHSV include, but are not limited to talimogene laherparepvec (U.S. Pat.Nos. 7,223,593 and 7,537,924); OncoVEXGALV/CD (U.S. Pat. No. 7,981,669);OrienX010 (Lei et al. (2013), World J. Gastroenterol., 19:5138-5143);G207, 1716; NV1020; NV12023; NV1034 and NV1042 (Vargehes et al. (2002),Cancer Gene Ther., 9(12):967-978).

Also included are TIMPs. TIMPs are endogenous tissue inhibitors ofmetalloproteinases (TIMPs) and are important in many natural processes.TIMP-3 is expressed by various cells or and is present in theextracellular matrix; it inhibits all the major cartilage-degradingmetalloproteases, and may play a role in role in many degradativediseases of connective tissue, including rheumatoid arthritis andosteoarthritis, as well as in cancer and cardiovascular conditions. Theamino acid sequence of TIMP-3, and the nucleic acid sequence of a DNAthat encodes TIMP-3, are disclosed in U.S. Pat. No. 6,562,596, issuedMay 13, 2003, the disclosure of which is incorporated by referenceherein. Description of TIMP mutations can be found in U.S. PublicationNo. 2014/0274874 and PCT Publication No. WO 2014/152012.

Also included are antagonistic antibodies for human calcitoningene-related peptide (CGRP) receptor and bispecific antibody moleculethat target the CGRP receptor and other headache targets. Furtherinformation concerning these molecules can be found in PCT ApplicationNo. WO 2010/075238.

Additionally, bispecific T cell engager (BiTE®) antibodies, e.g.BLINCYTO® (blinatumomab), can be used in the device. Alternatively,included can be an APJ large molecule agonist e.g., apelin or analoguesthereof in the device. Information relating to such molecules can befound in PCT Publication No. WO 2014/099984.

In certain embodiments, the medicament comprises a therapeuticallyeffective amount of an anti-thymic stromal lymphopoietin (TSLP) or TSLPreceptor antibody. Examples of anti-TSLP antibodies that may be used insuch embodiments include, but are not limited to, those described inU.S. Pat. Nos. 7,982,016, and 8,232,372, and U.S. Publication No.2009/0186022. Examples of anti-TSLP receptor antibodies include, but arenot limited to, those described in U.S. Pat. No. 8,101,182. Inparticularly preferred embodiments, the medicament comprises atherapeutically effective amount of the anti-TSLP antibody designated asA5 within U.S. Pat. No. 7,982,016.

Although the on-body injector, syringe adapter, needle cover guide,systems, methods, and elements thereof, have been described in terms ofexemplary embodiments, they are not limited thereto. The detaileddescription is to be construed as exemplary only and does not describeevery possible embodiment of the invention because describing everypossible embodiment would be impractical, if not impossible. Numerousalternative embodiments could be implemented, using either currenttechnology or technology developed after the filing date of this patentthat would still fall within the scope of the claims defining theinvention.

It should be understood that the legal scope of the invention is definedby the words of the claims set forth at the end of this patentapplication. The appended claims should be construed broadly to includeother variants and embodiments of same, which may be made by thoseskilled in the art without departing from the scope and range ofequivalents of the device, needle cover guide, prefilled syringeadapter, systems, methods, and their elements.

What is claimed:
 1. An on-body injector system comprising: an on-bodyinjector comprising: a housing having an interior surface defining aninterior cavity and an exterior surface, a reservoir disposed within theinterior cavity and configured to receive a volume of a drug, and a fillport having an inlet disposed on the exterior surface of the housing,the fill port being in fluid communication with the reservoir; a needlecover attached to a portion of the exterior surface of the housing andcovering the fill port, the needle cover comprising a guide aligned withthe fill port, the guide having an interior surface defining a bore; andan adapter configured to be received within the guide of the needlecover, the adapter configured to stabilize a prefilled syringe forfilling the reservoir.
 2. The system of claim 1, wherein the adapter isconfigured to be mechanically coupled to the bore of the guide of theneedle cover.
 3. The system of claim 1, wherein the adapter ismechanically coupled to the bore of the guide of the needle cover. 4.The system of claim 1, wherein the adapter has a frustoconical portionthat is received in a tapered interior surface of the guide.
 5. Thesystem of claim 4, wherein the frustoconical portion of the adapter issubstantially complementary with the tapered interior surface of theguide.
 6. The system of claim 1, wherein the interior surface of theguide is straight-walled, and wherein the adapter further comprises astraight-walled exterior surface that is substantially complementarywith the straight-walled interior surface of the guide.
 7. The system ofclaim 1, wherein the adapter further comprises a compressive O-ringdisposed on the exterior surface of the adapter.
 8. The system of claim1, wherein the adapter further comprises an exterior surface having adetent, and wherein the guide further comprises a groove formed in theinterior surface of the guide and configured to receive the detent whenthe adapter is positioned inside the bore of the guide.
 9. The system ofclaim 1, wherein the adapter further comprises a male lock fitting andthe guide comprises a female lock fitting configured to couple to themale lock fitting when the adapter is inserted into the bore of theguide.
 10. The system of claim 1, wherein the adapter and the guide aremechanically coupled by friction fit when the adapter is positionedinside the bore of the guide.
 11. The system of claim 1, wherein theguide further comprises a shoulder having a surface disposed inside thebore and the adapter further includes a nose having a surface that issubstantially complementary with the surface of the shoulder and isconfigured to mate with the surface of the shoulder when the guide andthe adapter are mechanically coupled.
 12. The system of claim 1, whereinthe adapter further comprises a female lock fitting and the guidecomprises a male lock fitting configured to couple to the female lockfitting when the adapter is inserted into the bore of the guide.
 13. Thesystem of claim 1, wherein the guide further comprises a detent disposedon the interior surface of the guide, and wherein the adapter furthercomprises an exterior surface having a groove that is configured toreceive the detent when the adapter is positioned inside the bore of theguide.
 14. The system of claim 1, wherein the adapter and the guide aremagnetically coupled when the adapter is positioned inside the bore ofthe guide.
 15. The system of claim 1, further comprising: a prefilledsyringe comprising: a barrel having a distal end and a barrel reservoircontaining a volume of a drug, and a needle in fluid communication withthe barrel reservoir and disposed at the distal end of the barrel,wherein the distal end of the barrel is configured to be coupled to theadapter for stabilizing the prefilled syringe when the adapter ispositioned inside of the bore of the guide.
 16. The system of claim 15,wherein a tip of the needle of the prefilled syringe is positionedwithin the fill port when the distal end of the barrel is coupled to theadapter and the adapter is positioned inside of the bore of the guide.